Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Classical hematology 3Thoracic 1

Conditions

Anemia 2Renal Anemia 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 58Busulfan 47fludarabine phosphate 45Cyclosporine 34Mycophenolic Acid 31Whole-Body Irradiation 29Peripheral Blood Stem Cell Transplantation 29fludarabine 27Antilymphocyte Serum 27Tacrolimus 26Methotrexate 25Melphalan 25Filgrastim 20Radiotherapy 19Darbepoetin alfa 19Cytarabine 19Cord Blood Stem Cell Transplantation 18Epoetin Alfa 17Granulocyte Colony-Stimulating Factor 14Methylprednisolone 13thymoglobulin 10Thiotepa 9Etoposide 9Alemtuzumab 9eltrombopag 8Stem Cell Transplantation 8olaparib 7sargramostim 6hetrombopag 6Rituximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × continuous erythropoietin receptor activator × Classical hematology × Clear all
NCT00717366 2017-09-08

Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis

Hoffmann-La Roche

Phase 2 Completed
64 enrolled 15 charts 1 FDA
Classical hematology

Renal Anemia

NCT00327535 2016-08-11

A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Hoffmann-La Roche

Phase 2 Completed
153 enrolled
Classical hematology

Anemia

NCT00072059 2013-07-18

Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Classical hematologyThoracic

Anemia, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡